تقرير
أعرض في EDS

Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis.

التفاصيل البيبلوغرافية
العنوان: Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis.
المؤلفون: Kim H; Juvenile Myositis Pathogenesis and Therapeutics Unit, NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA hanna.kim@nih.gov.; Pediatric Clinical Trials Unit, NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA., Dill S; Pediatric Clinical Trials Unit, NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA.; Office of the Clinical Director, NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA., O'Brien M; Pediatric Clinical Trials Unit, NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA.; Office of the Clinical Director, NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA., Vian L; Translational Immunology Section, NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA., Li X; Biostatistics and Clinical Epidemiology Service, National Institutes of Health Clinical Center, Bethesda, Maryland, USA., Manukyan M; Pediatric Clinical Trials Unit, NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA.; Office of the Clinical Director, NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA., Jain M; Rehabilitation Medicine Department, Physical Therapy Section, National Institutes of Health Clinical Center, Bethesda, Maryland, USA., Adeojo LW; Clinical Pharmacokinetics Research Unit, Pharmacy Department, National Institutes of Health Clinical Center, Bethesda, Maryland, USA., George J; Clinical Pharmacokinetics Research Unit, Pharmacy Department, National Institutes of Health Clinical Center, Bethesda, Maryland, USA., Perez M; Pediatric Rheumatology, Cook Children's Medical Center, Fort Worth, Texas, USA., Grom AA; Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA., Sutter M; Department of Rheumatology, Children's Hospital Colorado, Aurora, Colorado, USA.; Pediatrics Rheumatology, University of Colorado Denver, Denver, Colorado, USA., Feldman BM; Division of Rheumatology, Hospital for Sick Children, Toronto, Ontario, Canada.; Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada., Yao L; Radiology and Imaging Sciences, National Institutes of Health Clinical Center, Bethesda, Maryland, USA., Millwood M; Pediatric Clinical Trials Unit, NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA.; Office of the Clinical Director, NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA., Brundidge A; Pediatric Clinical Trials Unit, NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA.; Office of the Clinical Director, NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA., Pichard DC; Dermatology Branch, NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA., Cowen EW; Dermatology Branch, NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA., Shi Y; Office of the Clinical Director, NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA., Lu S; Translational Immunology Section, NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA., Tsai WL; Translational Immunology Section, NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA., Gadina M; Translational Immunology Section, NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA., Rider LG; Environmental Autoimmunity Group, NIEHS/NIH/DHHS, Bethesda, Maryland, USA., Colbert RA; Pediatric Clinical Trials Unit, NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA.; Office of the Clinical Director, NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA.
المصدر: Annals of the rheumatic diseases [Ann Rheum Dis] 2021 Mar; Vol. 80 (3), pp. 406-408. Date of Electronic Publication: 2020 Aug 25.
نوع المنشور: Letter; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Intramural
اللغة: English
بيانات الدورية: Publisher: BMJ Country of Publication: England NLM ID: 0372355 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-2060 (Electronic) Linking ISSN: 00034967 NLM ISO Abbreviation: Ann Rheum Dis Subsets: MEDLINE
أسماء مطبوعة: Publication: London : BMJ
Original Publication: London : H.K. Lewis
مواضيع طبية MeSH: Azetidines*/pharmacology , Azetidines*/therapeutic use , Dermatomyositis*/drug therapy, Humans ; Janus Kinase 1 ; Janus Kinase 2 ; Janus Kinases ; Purines/therapeutic use ; Pyrazoles ; Sulfonamides
مستخلص: Competing Interests: Competing interests: None declared.
معلومات مُعتمدة: Z99 AR999999 United States ImNIH Intramural NIH HHS; ZIA AR041184 United States ImNIH Intramural NIH HHS; ZIA ES101081 United States ImNIH Intramural NIH HHS; ZID AR041180 United States ImNIH Intramural NIH HHS
فهرسة مساهمة: Keywords: cytokines; dermatomyositis; therapeutics
سلسلة جزيئية: ClinicalTrials.gov NCT01724580
المشرفين على المادة: 0 (Azetidines)
0 (Purines)
0 (Pyrazoles)
0 (Sulfonamides)
EC 2.7.10.2 (Janus Kinase 1)
EC 2.7.10.2 (Janus Kinase 2)
EC 2.7.10.2 (Janus Kinases)
ISP4442I3Y (baricitinib)
تواريخ الأحداث: Date Created: 20200827 Date Completed: 20220627 Latest Revision: 20220716
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC7904969
DOI: 10.1136/annrheumdis-2020-218690
PMID: 32843325
قاعدة البيانات: MEDLINE
الوصف
تدمد:1468-2060
DOI:10.1136/annrheumdis-2020-218690